FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc

Resistance to epidermal growth factor receptor (EGFR) targeted monoclonal antibody therapy represents a clinical challenge in patients suffered from RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, the molecular mechanisms and key factors conferring this resistance are largely unknow...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yiyi, Guo, Mengzhou, Wei, Ye, Yu, Shan, Li, Hong, Wang, Yan, Xu, Xiaojing, Cui, Yuehong, Tian, Jiawen, Liang, Li, Peng, Ke, Liu, Tianshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348362/
https://www.ncbi.nlm.nih.gov/pubmed/27825133
http://dx.doi.org/10.18632/oncotarget.13105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348362/
https://www.ncbi.nlm.nih.gov/pubmed/27825133
http://dx.doi.org/10.18632/oncotarget.13105

Ejemplares similares